UCSF researchers have pinpointed a crucial brain receptor that helps immune cells called microglia clear out toxic amyloid ...

FDA provides pivotal agreement on EB613 Phase 3 design, confirming Bone Mineral Density (BMD) as primary endpoint and clearing streamlin ...

FDA provides pivotal agreement on EB613 Phase 3 design, confirming Bone Mineral Density (BMD) as primary endpoint and clearing streamlined pathway for first oral anabolic osteoporosis treatmentSignifi ...

ABCL-575’s predicted dosing schedule of every six months is enabled by a "human half-life of approximately 67 days," as ...

Added to Russell 3000® Index: In June 2025, Tectonic was added to the Russell 3000® Index as part of FTSE Russell’s annual reconstitution. Inclusion in the index broadens the company’s exposure to ...

In a combined analysis of patients from five open-label trials, 22 percent responded to the protease activator, the first approved treatment for the rare disease.

The story of the discovery of these molecules 50 years ago shows how the free exchange of ideas can lead to life-changing ...

The FDA has granted accelerated approval to dordaviprone for use in adult and pediatric patients with H3 K27M-mutated diffuse midline glioma.

LMO2 is an intrinsically disordered transcription factor activated in T cell leukaemia that is difficult to target. It forms part of a multiprotein complex that has bipartite DNA binding through ...

This is a valuable computational study of odor responses in the early olfactory system of insects and vertebrates. The study addresses the question of how information about odor concentration is ...

Revvity, Inc. (NYSE: RVTY), today announced the launch of pHSense™ reagents, a powerful technology designed to advance ...

Lactic acid (LA) has transitioned from being perceived as a mere glycolytic waste product to a pivotal regulator of ...